TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8923126

Group type: EXPERIMENTAL
Intervention: Milnacipran (50 mg twice a day)
Number of subjects: 5732

Group type: COMPARATOR
Intervention: SSRIs (Fluoxetine 20 mg once a day and Fluvoxamine 100 mg twice a day)
Number of subjects: 5732

Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 5732

Group type: COMPARATOR
Intervention: SSRIs
Number of subjects: 5732
Study: 1673110

Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg (b.i.d.)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg (b.i.d.)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg (b.i.d.)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study: 6779652

Group type: EXPERIMENTAL
Intervention: Selective hyperalimentation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard hyperalimentation
Number of subjects: 50
Study: 31295270

Group type: EXPERIMENTAL
Intervention: Mindfulness training (Monitor+Accept)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mindfulness training (Monitor Only)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both mindfulness interventions (Monitor+Accept and Monitor Only)
Number of subjects: 0
Study: 28423524

Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (80 mg/m2 for 12 weeks)
Number of subjects: 115
Study: 26426352

Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Cilostazol (100 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Clopidogrel + Cilostazol
Number of subjects: 27

Group type: COMPARATOR
Intervention: Clopidogrel alone
Number of subjects: 27
Study: 24858885

Group type: EXPERIMENTAL
Intervention: Get Healthy Together (GHT) intervention
Number of subjects: 48
Study: 22227457

Group type: EXPERIMENTAL
Intervention: Generate condition
Number of subjects: 49

Group type: COMPARATOR
Intervention: Read condition
Number of subjects: 49
Study: 19642225

Group type: EXPERIMENTAL
Intervention: Ablation of continuous complex fractionated atrial electrograms (CFEs) in the left atrium/coronary sinus
Number of subjects: 60

Group type: COMPARATOR
Intervention: Pulmonary vein isolation (PVI) plus linear ablation without additional ablation of CFEs
Number of subjects: 60
Study: 17403225

Group type: EXPERIMENTAL
Intervention: Submandibular duct relocation plus excision of the sublingual glands
Number of subjects: 100

Group type: COMPARATOR
Intervention: Submandibular duct relocation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both procedures
Number of subjects: 100
Study: 11108069

Group type: EXPERIMENTAL
Intervention: Telephone call reminder within three days of ED attendance
Number of subjects: 400

Group type: COMPARATOR
Intervention: Control group (no telephone call reminder)
Number of subjects: 400
Study: 9344199

Group type: EXPERIMENTAL
Intervention: Combination clindamycin/benzoyl peroxide gel
Number of subjects: 334

Group type: COMPARATOR
Intervention: Clindamycin gel
Number of subjects: 334

Group type: COMPARATOR
Intervention: Benzoyl peroxide gel
Number of subjects: 334

Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 334
Study: 8384978

Group type: EXPERIMENTAL
Intervention: 1.5 million units of recombinant alpha‐2a‐interferon subcutaneously, thrice weekly, for six months
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Interferon-treated responders
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: All treated patients
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Nonresponders
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Responders
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Posttherapy follow-up
Number of subjects: 32
Study: 3099273

Group type: EXPERIMENTAL
Intervention: Topical glyceryl trinitrate
Number of subjects: 17
Study: 28618046

Group type: EXPERIMENTAL
Intervention: Bundle care intervention group (n=58)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Routine nurse control group (n=56)
Number of subjects: 114
Study: 27456379

Group type: EXPERIMENTAL
Intervention: Chan‐Chuang qigong exercise (20-min twice daily for 21 days)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group (no special exercise intervention)
Number of subjects: 108
Study: 25172376

Group type: COMPARATOR
Intervention: Benzathine benzylpenicillin
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Co-trimoxazole (pooled)
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Twice-daily co-trimoxazole for 3 days
Number of subjects: 508

Group type: EXPERIMENTAL
Intervention: Once-daily co-trimoxazole for 5 days
Number of subjects: 508
Study: 23740801

Group type: EXPERIMENTAL
Intervention: 400 mg ocrelizumab
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: 1,000 mg ocrelizumab
Number of subjects: 378

Group type: EXPERIMENTAL
Intervention: Combined ocrelizumab-treated groups
Number of subjects: 378

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 378
Study: 20803853

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (IIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 0
Study: 18805718

Group type: EXPERIMENTAL
Intervention: Immediate implants augmented with autogenous bone graft
Number of subjects: 20

Group type: COMPARATOR
Intervention: Immediate implants augmented with synthetic bone graft
Number of subjects: 20
Study: 16466172

Group type: EXPERIMENTAL
Intervention: Chinese herbal treatment for clearing heat, detoxicating and nourishing Yin (CHM)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Oral administration of loratadine 10 mg once a day and ketotifen 1 mg once every night
Number of subjects: 115
Study: 12833109

Group type: EXPERIMENTAL
Intervention: SCHO breakfast
Number of subjects: 26

Group type: COMPARATOR
Intervention: CCHO breakfast
Number of subjects: 26
Study: 10927729

Group type: EXPERIMENTAL
Intervention: Deception to avoid exchanging call
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Misrepresenting a diagnosis in a medical record to protect patient privacy
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Fabricating a laboratory value to an attending physician
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Substituting their own urine in a drug test to protect a colleague
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Lying about checking a patient's stool for blood to cover up a medical mistake
Number of subjects: 221
Study: 8777828

Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Oral theophylline (10-20 mg/l blood levels)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Inhaled cromoglycate
Number of subjects: 12

Group type: COMPARATOR
Intervention: Inhaled salbutamol (as required)
Number of subjects: 12
Study: 30114246

Group type: EXPERIMENTAL
Intervention: Higher dose of detemir (1.6 U/kg body weight)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Higher dose of glargine (1.6 U/kg body weight)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Glargine (1.6 U/kg body weight) during last 6 hours of the clamp
Number of subjects: 10
Study: 26216048

Group type: EXPERIMENTAL
Intervention: Micafungin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Voriconazole
Number of subjects: 0
Study: 23795552

Group type: EXPERIMENTAL
Intervention: Dynamic, visual-only exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Audiovisual speech (inter-sensory redundancy)
Number of subjects: 0
Study: 23234771

Group type: EXPERIMENTAL
Intervention: Duo positive airway pressure (DuoPAP)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Nasal continuous positive airway pressure (NCPAP)
Number of subjects: 67
Study: 20634742

Group type: EXPERIMENTAL
Intervention: Cocoa-based protein and carbohydrate drink
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (no drink)
Number of subjects: 7
Study: 18479755

Group type: EXPERIMENTAL
Intervention: Electronic molecular resonance bipolar tonsillectomy (EMRBT)
Number of subjects: 800

Group type: COMPARATOR
Intervention: Blunt dissection tonsillectomy
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 800
Study: 15719743

Group type: EXPERIMENTAL
Intervention: Shennong Ganzhining (SG)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Zhibituo treatment
Number of subjects: 190
Study: 12830408

Group type: EXPERIMENTAL
Intervention: Recombinant human drotrecogin alfa (activated) (DrotAA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11012953

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1% (R 0.1)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% (R 0.2)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Bupivacaine 0.2% (B 0.2)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.1% (R 0.1) and Ropivacaine 0.2% (R 0.2)
Number of subjects: 3
Study: 8659471

Group type: EXPERIMENTAL
Intervention: Harvold activator
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Fränkel function regulator
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control
Number of subjects: 42
Study: 1325321

Group type: EXPERIMENTAL
Intervention: Maximal exercise for 4 minutes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 99mTc‐labelled erythrocytes
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 111In‐labelled platelets
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: 111In‐labelled granulocytes
Number of subjects: 10
Study: 6401878

Group type: EXPERIMENTAL
Intervention: Aspirin (1 g/day)
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Aspirin (1 g/day) + Dipyridamole (225 mg/day)
Number of subjects: 604

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Aspirin (1 g/day) and Aspirin (1 g/day) + Dipyridamole (225 mg/day) combined
Number of subjects: 604
Study: 31686181

Group type: EXPERIMENTAL
Intervention: Unicompartmental knee arthroplasty (UKA)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 35
Study: 31000233

Group type: EXPERIMENTAL
Intervention: Guidelines Daily Amount (GDA)
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Traffic Light System (TLS)
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Nutritional Warnings
Number of subjects: 492
Study: 30015676

Group type: EXPERIMENTAL
Intervention: 1-day initiation regimen (single ALNCD injection + one 30-mg dose of oral aripiprazole on day 1)
Number of subjects: 161

Group type: COMPARATOR
Intervention: 21-day initiation regimen (15-mg daily dose of oral aripiprazole for 21 days)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: 1-day initiation regimen
Number of subjects: 161

Group type: COMPARATOR
Intervention: 21-day initiation regimen
Number of subjects: 161
Study: 26728002

Group type: EXPERIMENTAL
Intervention: Repeated and Reinforced Oral Health Education (RR-OHE)
Number of subjects: 935

Group type: COMPARATOR
Intervention: One-time Oral Health Education (OHE) by dentist and peer-leaders
Number of subjects: 935

Group type: COMPARATOR
Intervention: One-time Oral Health Education (OHE) by teachers
Number of subjects: 935

Group type: COMPARATOR
Intervention: One-time OHE for all groups
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: RR-OHE after 6 months
Number of subjects: 935

Group type: EXPERIMENTAL
Intervention: 12-month evaluation of RR-OHE
Number of subjects: 935
Study: 24992083

Group type: EXPERIMENTAL
Intervention: Piribedil
Number of subjects: 80

Group type: COMPARATOR
Intervention: Pramipexole or Ropinirole
Number of subjects: 80
Study: 22523038

Group type: EXPERIMENTAL
Intervention: Kurzweil 3000 (K‐3000)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (using pen and paper)
Number of subjects: 29
Study: 19580131

Group type: EXPERIMENTAL
Intervention: Remifentanil perfusion at 1 microg x kg(‐1) x min(‐1) until intubation
Number of subjects: 54

Group type: COMPARATOR
Intervention: Fentanyl bolus dose of 2 microg x kg(‐1)
Number of subjects: 54
Study: 17592713

Group type: EXPERIMENTAL
Intervention: Cryotherapy at 45 degrees F
Number of subjects: 64

Group type: COMPARATOR
Intervention: Cryotherapy at 75 degrees F
Number of subjects: 64
Study: 16254088

Group type: EXPERIMENTAL
Intervention: Egalitarian group structure (democratic decision-making procedures)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Hierarchical group structure (authoritarian decision-making procedures)
Number of subjects: 0
Study: 11888261

Group type: EXPERIMENTAL
Intervention: Add-on studies with new AEDs for bipolar disorder
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-controlled trials in epilepsy
Number of subjects: 0
Study: 10331996

Group type: EXPERIMENTAL
Intervention: Specialist health visitor intervention
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control (conventional care)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Specialist health visitor intervention (children < 12 months)
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control (children < 12 months)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study: 7795095

Group type: EXPERIMENTAL
Intervention: Ofloxacin 15 mg/kg daily for 3 days
Number of subjects: 438

Group type: EXPERIMENTAL
Intervention: Ofloxacin 10 mg/kg daily for 5 days
Number of subjects: 438

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 438
Study: 2219338

Group type: EXPERIMENTAL
Intervention: UW solution
Number of subjects: 0
Study: 348379

Group type: EXPERIMENTAL
Intervention: Diflunisal, 250 mg twice daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA), 750 mg 4 times daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA), 600 mg 4 times daily
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Diflunisal
Number of subjects: 12

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA) with alcohol
Number of subjects: 12
Study: 30633363

Group type: EXPERIMENTAL
Intervention: Biochemically confirmed smoking cessation (quitters)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Continuing smokers (control)
Number of subjects: 0
Study: 27752993

Group type: EXPERIMENTAL
Intervention: BEAT Cancer intervention
Number of subjects: 222

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 222
Study: 25844638

Group type: EXPERIMENTAL
Intervention: Full-active condition (visuospatial WM, inhibition, cognitive-flexibility training)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Partially-active condition (inhibition and cognitive-flexibility training, WM training in placebo-mode)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Full placebo condition
Number of subjects: 89
Study: 23963035

Group type: COMPARATOR
Intervention: Metal-on-polyethylene bearings
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Metal-on-metal bearings
Number of subjects: 92
Study: 21291959

Group type: EXPERIMENTAL
Intervention: Real tDCS with hand movements
Number of subjects: 12

Group type: COMPARATOR
Intervention: Sham tDCS with hand movements
Number of subjects: 12
Study: 19188412

Group type: EXPERIMENTAL
Intervention: Vitremer Tri-Cure Glass Ionomer System (3M ESPE Dental Products)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Freedom (SDI)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: TPH Spectrum (Dentsply)
Number of subjects: 48
Study: 17311843

Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate/salmeterol combination treatment
Number of subjects: 911

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 911
Study: 14993512

Group type: EXPERIMENTAL
Intervention: AVF thrombosis
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Baseline vascular access blood flow rate <700 ml/min
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: AVFs with baseline blood flow rates >700 ml/min
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: AVFs with baseline blood flow rates <700 ml/min
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: 4 year cumulative actuarial survival
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: AVFs remaining patent at the end of 4 years
Number of subjects: 52
Study: 12585145

Group type: EXPERIMENTAL
Intervention: Needling at Yang MP (Hegu, Quchi, Zusanli, Shangjuxu)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Needling at Yin MP (Neiguan, Chize, Sanyinjiao, Yinlingquan)
Number of subjects: 30
Study: 9719081

Group type: EXPERIMENTAL
Intervention: High-dose intensity
Number of subjects: 1550

Group type: EXPERIMENTAL
Intervention: Moderate-dose intensity
Number of subjects: 1550

Group type: COMPARATOR
Intervention: Low-dose intensity
Number of subjects: 1550
Study: 7715258

Group type: EXPERIMENTAL
Intervention: Continuous perfusion of NTG at 2 mg/h (Group A)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Continuous perfusion of NTG at 4 mg/h (Group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo (subgroup A1 and B1)
Number of subjects: 40
Study: 2516609

Group type: EXPERIMENTAL
Intervention: r‐HuEPO 50 U/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: r‐HuEPO 100 U/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: r‐HuEPO 150 U/kg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: r‐HuEPO maintenance phase
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: r‐HuEPO
Number of subjects: 24
Study: 144509

Group type: EXPERIMENTAL
Intervention: Rheumon Gel (etofenamate)
Number of subjects: 760

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 760

Group type: COMPARATOR
Intervention: Ointment I (2-hydroxyethyl salicylate and p-menthan-3-ol)
Number of subjects: 760

Group type: COMPARATOR
Intervention: Ointment II (3,5-dioxo-1,2-diphenyl-4-n-butylpyrazolidine)
Number of subjects: 760
Study: 31734638

Group type: EXPERIMENTAL
Intervention: Whole-body MRI including DWI/T2-weighted fused images
Number of subjects: 21

Group type: COMPARATOR
Intervention: Whole-body MRI without fused images
Number of subjects: 21
Study: 28124585

Group type: EXPERIMENTAL
Intervention: Thalidomide (400 mg daily)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 25937055

Group type: EXPERIMENTAL
Intervention: MgCl2 5% solution (30 mL, equivalent to 382 mg of magnesium)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 116
Study: 23710976

Group type: EXPERIMENTAL
Intervention: Methylphenidate or dexamphetamine (titrated doses)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 22009030

Group type: EXPERIMENTAL
Intervention: Uninterrupted treatment (arm A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: 2-week additional period of rest between FEC and docetaxel (arm B)
Number of subjects: 120
Study: 19339674

Group type: EXPERIMENTAL
Intervention: Pulpdent silane and Unite bonding adhesive with 9.6% HF acid (Group 1)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Reliance silane and Unite bonding adhesive with 9.6% HF acid (Group 2)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Pulpdent silane and Unite bonding adhesive with 5% HF acid (Group 3)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Reliance silane and Unite bonding adhesive with 5% HF acid (Group 4)
Number of subjects: 80
Study: 16780258

Group type: EXPERIMENTAL
Intervention: Ebstein anomaly patients
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: ASD II patients
Number of subjects: 56
Study: 15515752

Group type: EXPERIMENTAL
Intervention: Bone scintigraphy with technetium‐99m‐hydroxy‐methylene‐diphosphonate (99mTc‐HMDP)
Number of subjects: 28
Study: 11084783

Group type: EXPERIMENTAL
Intervention: Diabetic patients with autonomic neuropathy
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Diabetic patients without autonomic neuropathy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 50
Study: 8976637

Group type: EXPERIMENTAL
Intervention: Testosterone propionate 50 mg intramuscularly every two weeks for one year
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Testosterone propionate
Number of subjects: 107
Study: 2022477

Group type: EXPERIMENTAL
Intervention: Natural interleukin‐2 (nIL‐2) 200 U
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Natural interleukin‐2 (nIL‐2) 1,000 U
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Natural interleukin‐2 (nIL‐2) 5,000 U
Number of subjects: 20
Study: 7137536

Group type: EXPERIMENTAL
Intervention: Flunisolide 200 microgram per day
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 30808612

Group type: EXPERIMENTAL
Intervention: Verum (active) 2-mA tDCS
Number of subjects: 25

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Verum tDCS
Number of subjects: 25
Study: 28733159

Group type: EXPERIMENTAL
Intervention: Bladder training video (BTV)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard urotherapy (SU)
Number of subjects: 150
Study: 25287075

Group type: EXPERIMENTAL
Intervention: Experienced observers (7 members of the IST-3 expert image reading panel)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Radiology trainees (<2 years experience)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Intra-observer agreement among experts
Number of subjects: 15
Study: 25437223

Group type: EXPERIMENTAL
Intervention: Intravenous ferric carboxymaltose (500 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 22838957

Group type: EXPERIMENTAL
Intervention: Educational pamphlet about genetic testing
Number of subjects: 140

Group type: COMPARATOR
Intervention: Genetic counseling appointment at a family cancer center
Number of subjects: 140
Study: 20436978

Group type: EXPERIMENTAL
Intervention: 15 mg/kg acetaminophen rectally
Number of subjects: 60

Group type: COMPARATOR
Intervention: 15 mg/kg acetaminophen orally
Number of subjects: 60
Study: 17673105

Group type: EXPERIMENTAL
Intervention: Multiple baseline design
Number of subjects: 0

Group type: COMPARATOR
Intervention: Randomized controlled trial (RCT)
Number of subjects: 0
Study: 16165255

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 16

Group type: COMPARATOR
Intervention: Semi-recumbent position
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Supine position in non-refluxers
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Supine position in refluxers
Number of subjects: 16
Study: 11900816

Group type: EXPERIMENTAL
Intervention: Progesterone treatment (200 mg dose)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5